** Shares of cancer therapy maker Novocure NVCR.O up 2% at $16.84 premarket
** Company posts Q2 revenue of $158.8 million, compared with analysts' average expectations of $154.2 million - data compiled by LSEG
** J.P.Morgan says Q2 revenue "driven primarily by active patient growth across major markets"
** Novocure plans to submit a premarket approval application to the FDA for pancreatic cancer treatment in Q3 2025
** "We believe it may take getting closer to meaningful rev growth from these new opportunities for the stock to work," JPM adds
** Up to last close, stock down 44.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。